Latest On Adamis Pharmaceuticals Corporation (ADMP):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-19 20:46 EST | News | Adamis Pharma slips 19% on plans for reverse stock slip | N/A |  |
| 2023-05-15 20:16 EST | News | Adamis Pharmaceuticals GAAP EPS of -$0.06, revenue of $1.45M | N/A | |
| 2023-05-15 20:15 EST | News | Adamis Pharmaceuticals Corporation (ADMP) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-03-17 20:15 EST | News | Adamis Pharmaceuticals Corporation (ADMP) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-17 05:01 EST | News | Adamis Pharmaceuticals GAAP EPS of -$0.18, revenue of $4.75M | N/A | |
About Adamis Pharmaceuticals Corporation (ADMP):
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; Tadalafil (APC-8000) for the treatment of erectile dysfunction; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormon read more...e replacement therapies, hospital outsourcing products, injectables, urological preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
General
- Name Adamis Pharmaceuticals Corporation
- Symbol ADMP
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 131
- Last Split Factor1:17
- Last Split Date2013-12-13
- Fiscal Year EndDecember
- IPO Date1995-08-14
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.adamispharmaceuticals.com
Valuation
- Price/Sales (Trailing 12 Mt.) 4.19
- Price/Book (Most Recent Quarter) 5.68
- Enterprise Value Revenue 8.15
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.06
- Profit Margin -188%
- Operating Margin -158%
- Return on Assets -38%
- Return on Equity -103%
- Revenue 18.43 million
- Earnings Per Share -$0.83
- Revenue Per Share $0.27
- Gross Profit 6.31 million
- Quarterly Earnings Growth -27.1%
Highlights
- Market Capitalization 145.89 million
- EBITDA -35849880
- PE Ratio -0.29
- Analyst Target Price $1
- Book Value Per Share $0.29
Share Statistics
- Shares Outstanding 140.28 million
- Shares Float 92.97 million
- % Held by Insiders 80%
- % Held by Institutions 7.05%
- Shares Short 3.24 million
- Shares Short Prior Month 4.13 million
- Short Ratio 0.19
- Short % of Float 2%
- Short % of Shares Outstanding 2%
Technicals
- Beta 1.41
- 52 Week High $1.8
- 52 Week Low $0.32
- 50 Day Moving Average 1.22
- 200 Day Moving Average 0.84
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Adamis Pharmaceuticals Corporation (ADMP) Dividend Calendar:
Adamis Pharmaceuticals Corporation (ADMP) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Adamis Pharmaceuticals Corporation (ADMP) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Adamis Pharmaceuticals Corporation (ADMP) Chart:
Adamis Pharmaceuticals Corporation (ADMP) News:
Below you will find a list of latest news for Adamis Pharmaceuticals Corporation (ADMP) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Adamis Pharmaceuticals Corporation (ADMP) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ADMP Trades:
Adamis Pharmaceuticals Corporation (ADMP) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-14 | 424B3 (Prospectus [Rule 424(b)(3)]) | |
| 2020-10-14 | EFFECT (Notice of Effectiveness) | |
| 2020-10-05 | 8-K (Current report) | |
| 2020-10-05 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-10-02 | 8-K (Current report) | |
| 2020-10-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-01 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-21 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-09-18 | 8-K (Current report) | |
| 2020-09-17 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-09-15 | 8-K (Current report) | |
| 2020-09-08 | 8-K (Current report) | |
| 2020-09-08 | 8-K (Current report) | |
| 2020-08-25 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-08-24 | 8-K (Current report) | |
| 2020-08-24 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-08-21 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-08-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-20 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-20 | 4 (Statement of changes in beneficial ownership of securities) | |
Adamis Pharmaceuticals Corporation (ADMP) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Adamis Pharmaceuticals Corporation (ADMP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 80%
Institutional Ownership: 705%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-29 | Robert O Hopkins | Chief Financial Officer | Sell | 20,000.00 | 0.80 | 16,000.00 | 274,781.00 | |
| 2020-09-29 | David J. Marguglio | SVP and Chief Business Officer | Sell | 20,000.00 | 0.80 | 16,000.00 | 308,539.00 | |
| 2020-08-18 | Karen K. Daniels | VP of Operations | Sell | 5,480.00 | 0.87 | 4,790.07 | 140,664.00 | |
| 2020-08-18 | Ronald B. Moss | Chief Medical Officer | Sell | 8,749.00 | 0.87 | 7,647.50 | 226,373.00 | |
| 2020-08-18 | Robert O Hopkins | Chief Financial Officer | Sell | 7,418.00 | 0.87 | 6,484.07 | 294,781.00 | |
| 2020-08-18 | DENNIS J PHD CARLO | President & CEO | Sell | 10,929.00 | 0.87 | 9,553.04 | 299,247.00 | |
| 2020-08-18 | David J. Marguglio | SVP and Chief Business Officer | Sell | 8,749.00 | 0.87 | 7,647.50 | 328,539.00 | |
| 2020-05-19 | Karen K. Daniels | VP of Operations | Sell | 4,855.00 | 0.56 | 2,719.29 | 146,144.00 | |
| 2020-05-18 | Ronald B. Moss | Chief Medical Officer | Sell | 7,736.00 | 0.56 | 4,332.93 | 235,122.00 | |
| 2020-05-18 | Robert O Hopkins | Chief Financial Officer | Sell | 6,532.00 | 0.56 | 3,658.57 | 302,199.00 | |
| 2020-05-18 | DENNIS J PHD CARLO | President & CEO | Sell | 9,913.00 | 0.56 | 5,552.27 | 310,176.00 | |
| 2020-05-18 | David J. Marguglio | SVP and Chief Business Officer | Sell | 7,734.00 | 0.56 | 4,331.81 | 337,288.00 | |
| 2020-03-18 | Karen K. Daniels | VP of Operations | Sell | 6,461.00 | 0.34 | 2,174.77 | 150,999.00 | |
| 2020-03-18 | Ronald B. Moss | Chief Medical Officer | Sell | 10,337.00 | 0.34 | 3,479.43 | 242,858.00 | |
| 2020-03-18 | Robert O Hopkins | Chief Financial Officer | Sell | 8,749.00 | 0.34 | 2,944.91 | 308,731.00 | |
| 2020-03-18 | DENNIS J PHD CARLO | President & CEO | Sell | 10,645.00 | 0.34 | 3,583.11 | 320,089.00 | |
| 2020-03-18 | David J. Marguglio | SVP and Chief Business Officer | Sell | 10,337.00 | 0.34 | 3,479.43 | 325,022.00 | |
| 2020-02-24 | Karen K. Daniels | VP of Operations | Sell | 6,229.00 | 0.60 | 3,759.20 | 157,460.00 | |
| 2020-02-24 | Ronald B. Moss | Chief Medical Officer | Sell | 6,229.00 | 0.06 | 395.54 | 253,195.00 | |
| 2020-02-24 | Robert O Hopkins | Chief Financial Officer | Sell | 8,420.00 | 0.60 | 5,081.47 | 317,480.00 | |